Immunotherapy in Gastrointestinal Malignancies

Adv Exp Med Biol. 2021:1342:259-272. doi: 10.1007/978-3-030-79308-1_8.

Abstract

Gastrointestinal (GI) cancers represent a heterogeneous group of malignancies, each with a unique tumor biology that in turn affects response to treatment and subsequent prognosis. The interplay between tumor cells and the local immune microenvironment also varies within each GI malignancy and can portend prognosis and response to therapy. Treatment with immune checkpoint inhibitors has changed the treatment landscape of various solid tumors including (but not limited to) renal cell carcinoma, melanoma, and lung cancer. Advances in the understanding between the interplay between the immune system and tumors cells have led to the integration of immunotherapy as standard of care in various GI malignancies. For example, immunotherapy is now a mainstay of treatment for tumors harboring defects in DNA mismatch repair proteins and tumors harboring a high mutational load, regardless of primary site of origin. Data from recent clinical trials have led to the integration of immunotherapy as standard of care for a subset of gastroesophageal cancers and hepatocellular carcinoma. Here, we outline the current landscape of immunotherapy in GI malignancies and highlight ongoing clinical trials that will likely help to further our understanding of how and when to integrate immunotherapy into the treatment of various GI malignancies.

Keywords: Cancer; Colon; Gastric; Immunotherapy; Liver.

MeSH terms

  • Clinical Trials as Topic
  • Esophageal Neoplasms / therapy
  • Gastrointestinal Neoplasms* / therapy
  • Humans
  • Immunotherapy*
  • Tumor Microenvironment